# SNWV earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SNWV) · [Earnings tab](https://www.lopjlb.com/stock/SNWV?tab=earnings)

Updated: 2026-11-07T06:05:05

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly call summaries, SANUWAVE moved from a phase of rapid top‑line expansion and successful debt restructuring (Q3 2024‑Q4 2025) to a period marked by modest revenue contraction and heightened regulatory pressure (Q4 2026‑Q2 2026). Early calls highlighted record revenues, expanding gross margins near 78 % and aggressive capital deployment to sales, manufacturing and a new applicator line. Milestones such as office relocation, sales‑territory staffing and debt refinancing were delivered on schedule, while the commercial production of the new applicator remained on‑track but delayed, pushing margin upside to early 2026. By late 2026 the company faced a sharp shift: CMS reimbursement cuts, audit clawbacks and a stretched sales cycle introduced new revenue‑risk themes, even as gross margin stayed robust through mix adjustments. Reseller channel expansion and active‑system tracking were progressing, yet the qualifying mold for the applicator line lagged. Overall, the narrative moves from growth‑driven optimism and milestone execution to a landscape dominated by reimbursement uncertainty, audit exposure and manufacturing delays, with earlier financing and concentration concerns largely resolved.

## Latest CallCard · Q2

SANUWAVE Q2 2026: Revenue $9.7M (-3% YoY) on 34% system sales drop from used device cannibalization; applicator volumes +27% YoY; CMS proposed rule threatens ~20% reimbursement cut; guidance withdrawn pending final rule Nov.','tone': {'mgmt': -0.1, 'mgmt_rationale': 'Management highlighted record ap

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** SANUWAVE Q2 2026: Revenue $9.7M (-3% YoY) on 34% system sales drop from used device cannibalization; applicator volumes +27% YoY; CMS proposed rule threatens ~20% reimbursement cut; guidance withdrawn pending final rule Nov.','tone': {'mgmt': -0.1, 'mgmt_rationale': 'Management highlighted record ap
- **2026 Q1:** SANUWAVE Q1 revenue record $9.6M (+3% YoY) as market thawed from CMS skin sub shock; guidance maintained $51-55M with seasonal back-half strength and large account evaluations.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlighted market thawing after CMS pricing shock, record applicator 
- **2025 Q4:** SANUWAVE posted record Q4 revenue and EBITDA, but faces CMS reimbursement cuts, audit clawbacks and a stretched sales cycle while expanding reseller channels and a new applicator line.
- **2025 Q3:** SANUWAVE posts record Q3 revenue of $11.5M (+22% YoY), sells 155 UltraMIST systems, refinances debt at lower rate, alleviates going concern doubt; CMS skin sub reimbursement clarity expected to unlock demand, guiding Q4 $13-14M.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights record 
- **2025 Q2:** SANUWAVE posted 42% Q2 revenue growth, lifted margins, expanded sales force, and previewed new applicator production and marketing plans, while noting debt refinancing and future margin upside.
- **2025 Q1:** —
- **2024 Q4:** SANUWAVE reports record Q4 revenue of $10.3M (47% YoY), gross margin 77.9%, initiates FY2025 guidance of $48-50M (50% growth), completes cap restructuring and NASDAQ uplisting, expands sales force and manufacturing capacity.','tone':{'mgmt':0.8,'mgmt_rationale':'Management highlights record revenue,
- **2024 Q3:** SANUWAVE reports record Q3 revenue of $9.4M (+89% YoY), achieves cash generation, completes debt restructuring, guides Q4 $9.7-10.5M, but notes lumpy systems sales from larger customers and ongoing manufacturing transition.','tone': {'mgmt': 0.5, 'mgmt_rationale': 'Management highlights record reven

## Theme arcs

- **Revenue trajectory** (improving): Record Q3 2024‑Q4 2025 growth followed by modest decline in Q2 2026 after CMS shock
- **Gross margin** (stable): Margins hovered around 77‑78 % with occasional upside expectations
- **Capital allocation** (new): Debt restructuring, refinancing and capex for sales force, manufacturing and reseller channels
- **Regulatory/reimbursement environment** (deteriorating): Initial clarity gave way to CMS cuts and audit clawbacks
- **Sales cycle dynamics** (deteriorating): Strong inbound interest but cycles stretched in late 2026
- **Customer concentration** (resolved): Early 5 % revenue threshold risk faded after growth
- **Manufacturing risk** (new): Delay in qualifying mold for new applicator line

## Fear persistence

- **Margin timing risk** [resolved]: Delay cleared as margin upside pushed to 2026
- **Large account conversion risk** [resolved]: Early pipeline uncertainty no longer highlighted
- **Debt refinancing risk** [resolved]: Refinancing completed by Q3 2025
- **Customer adoption skepticism** [resolved]: Record sales indicated acceptance
- **Customer concentration** [resolved]: No longer cited as a concern
- **Regulatory/reimbursement risk** [new]: CMS cut reimbursement by ~90 % in late 2026
- **Audit risk** [new]: Potential nine‑figure clawbacks introduced
- **Customer financial distress** [new]: Customers discontinuing systems after cash‑flow hits
- **Channel/inventory risk** [new]: Reseller shift creates inventory tracking challenges
- **Manufacturing risk** [new]: Delay in qualifying new applicator mold

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SNWV`